For decades, Alzheimer’s disease research has centered on two suspects: sticky amyloid-beta plaques and twisted tau tangles that accumulate in the brain. But despite billions of dollars poured into amyloid-targeting drugs, treatments remain mostly symptomatic, and many promising compounds have failed in clinical trials. A growing number of researchers are asking a different question: what if the immune system itself not just protein buildup is a primary driver of the disease?
A new study published in eNeuro in October 2025 explores this idea using cannabidiol (CBD), the non-psychoactive compound found in cannabis, as a tool to investigate and potentially calm this immune-driven inflammation in the brain. The results, while still in an early mouse model, offer an intriguing new angle on a disease that has stubbornly resisted treatment.
The “Autoinflammatory” Theory of Alzheimer’s
The traditional view of Alzheimer’s disease holds that amyloid-beta plaques trigger a cascade of damage that eventually destroys neurons and causes cognitive decline. But this model has gaps. Some people accumulate substantial amyloid plaques without ever developing dementia, while others show severe neurodegeneration with little amyloid or tau present at all.
An alternative framework, sometimes called the “autoinflammatory” theory of Alzheimer’s (researchers in this study refer to it as AD²), proposes that immune system dysfunction isn’t just a side effect of amyloid buildup it may be an early, independent driver of the disease. In this model, the brain’s resident immune cells become chronically overactive, attacking the brain’s own tissue and creating a self-perpetuating cycle of inflammation and neuronal damage.
Two molecular pathways sit at the center of this immune dysfunction, and they’re the focus of this new study: IDO and cGAS.
Meet the Pathways: IDO and cGAS
IDO (indoleamine 2,3-dioxygenase) is an enzyme involved in breaking down the amino acid tryptophan. Under normal circumstances, IDO helps keep the immune system in check. But in chronic inflammatory conditions like Alzheimer’s, IDO can become overactive, producing byproducts that are toxic to neurons and fuelling a self-sustaining inflammatory loop.
cGAS (cyclic GMP-AMP synthase) works through a completely different mechanism. It’s a sensor that detects DNA floating loose inside cells DNA that shouldn’t be there, often a sign of cellular damage. When cGAS detects this stray DNA, it triggers a cascade (via a partner protein called STING) that activates a powerful inflammatory immune response.
These two pathways operate independently, but they appear to converge on overlapping inflammatory outcomes, potentially creating a feedback loop that intensifies brain inflammation over time. Despite their importance, neither pathway has been well studied in the context of Alzheimer’s, which is what made them an attractive target for this research team.
The Experiment: CBD, Inhaled, in Mice With Alzheimer’s-Like Pathology
The researchers used 5xFAD mice a well-established genetic mouse model that develops amyloid plaques, brain inflammation, and cognitive decline, mimicking key features of human Alzheimer’s disease.
Mice aged 9 to 12 months (an age at which disease pathology is well established) were split into two groups of ten. One group received a daily inhaled dose of broad-spectrum CBD for four weeks; the other received a placebo (hemp seed oil, with no CBD). The researchers chose inhalation deliberately; this delivery method avoids the liver’s “first-pass metabolism,” which can break down a large portion of orally consumed CBD before it ever reaches the bloodstream, allowing for more predictable absorption into the brain.
After four weeks, the researchers examined brain tissue using fluorescence imaging and a technique called flow cytometry, which allows scientists to identify and count specific cell types and measure the proteins they produce. They also tested the mice’s memory and exploratory behavior and conducted computational analyses to predict which molecular targets CBD might interact with.
What They Found
1. CBD Reduced IDO Expression in Brain Immune Cells
In the entorhinal cortex, a brain region critical for memory and one of the earliest areas affected in Alzheimer’s, CBD-treated mice showed a significant drop in IDO expression in both microglia (the brain’s resident immune cells) and astrocytes (support cells that also play immune roles). This reduction was substantial and statistically robust.
2. CBD Reduced cGAS Activity Too
CBD treatment also significantly reduced the overlap between cGAS and IDO expression in brain cells, indicating that both inflammatory pathways were simultaneously dialed down. This is notable because it suggests CBD isn’t just nudging a single narrow mechanism but appears to influence a broader inflammatory network.
3. The Inflammatory Cytokine Profile Shifted Toward “Calm”
Using flow cytometry, the researchers measured levels of several signaling proteins called cytokines that immune cells use to communicate and coordinate inflammatory responses. CBD-treated mice showed significant reductions in three well-known pro-inflammatory cytokines, TNF-α, IL-1β, and IFN-γ, all of which have been repeatedly implicated in driving neuroinflammation in Alzheimer’s. At the same time, levels of IL-10, an anti-inflammatory cytokine that helps “put the brakes on” immune responses, increased significantly.
CBD treatment also reduced the number of infiltrating macrophages, immune cells that travel into the brain from the bloodstream during periods of inflammation, suggesting an overall calming of the brain’s immune environment.
4. An Interesting Twist: Microglia Became MORE Active, Astrocytes Became LESS Active
One of the more nuanced findings involved how the two main types of brain immune cells responded differently. CBD treatment was associated with increased activation markers in microglia, alongside decreased activation in astrocytes, though neither change reached statistical significance on its own.
Why might this matter? The researchers note that in the context of Alzheimer’s, this particular combination of more active microglia paired with calmer astrocytes is generally considered favorable. Microglia can help clear debris and damaged material when functioning well, while chronically overactive astrocytes are more often associated with sustained, harmful inflammation. The pattern observed here hints that CBD might be helping to rebalance, rather than simply suppress, the brain’s immune response.
5. Memory and Exploration Improved
Perhaps the most relatable finding for non-scientists: CBD-treated mice performed noticeably better on two standard behavioral tests.
In an open-field test in which mice are placed in a square arena and their movement is tracked, CBD-treated mice spent substantially more time exploring the central area (290 seconds versus 130 seconds in untreated mice), a pattern generally interpreted as reduced anxiety-like behavior and a healthier exploratory drive.
In a novel object recognition test, which measures whether mice remember a familiar object versus showing more interest in a new one, CBD-treated mice showed a strong preference for the new object (a “discrimination index” of about 0.5), while untreated mice actually showed a slight preference for the familiar object (a discrimination index of about −0.4), suggesting impaired recognition memory. This is a meaningful gap, and it links the molecular changes observed in the brain to an actual functional outcome.
Beyond IDO and cGAS: A Wider Molecular Web
The researchers also used a computational tool called STRING, which maps known and predicted protein interactions, to explore what else CBD might be interacting with within the brain’s immune network. Three molecules stood out as having strong predicted connections to CBD: AKT1, TRPV1, and GPR55.
AKT1 is involved in cell survival and immune regulation; TRPV1 is a channel that helps control calcium levels and inflammatory signaling in brain support cells; and GPR55 is a receptor involved in immune cell movement and activation. None of these were experimentally tested directly in this study; the connections are computational predictions, but they offer a roadmap for future research into exactly how CBD might be exerting its effects.
What This Means and What It Doesn’t
It’s important to be clear about the limits here. This is a mouse study, using a genetic model that doesn’t perfectly replicate human Alzheimer’s disease, which in most people develops sporadically rather than from inherited mutations. Only a single CBD dose was tested, and inhalation isn’t how most people currently access CBD products. The researchers themselves list these as limitations and call for broader dosing studies, additional immune cell types, and crucially, human clinical trials before any conclusions can be drawn about CBD as an Alzheimer’s treatment.
What this study adds is a mechanistic thread, a plausible biological story for how CBD’s known anti-inflammatory effects might translate into the brain via two specific, previously underexplored immune pathways. It’s a piece of a much larger puzzle, one that supports a broader shift in how some researchers are thinking about Alzheimer’s: not just as a disease of protein buildup, but as a disease in which the brain’s own immune system may be working against itself.
A Note on CBD and Self-Treatment
This research does not support self-treating Alzheimer’s disease, memory concerns, or any other condition with CBD products. The CBD used in this study was administered via a specialized inhaler at a controlled, research-grade dose under laboratory conditions a far cry from over-the-counter CBD products, which vary enormously in purity, dosage, and formulation. Anyone considering CBD for any health concern should speak with a healthcare provider first, particularly given potential interactions with other medications.
References
Emami Naeini S, Bhandari B, Hill B, Perez-Morales N, Rogers HM, Khodadadi H, Young N, Maciel LM, Yu JC, Hess DC, Morgan JC, Salles ÉL, Wang LP, Baban B. Rethinking Alzheimer’s: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control. eNeuro. 2025; 12(10). https://doi.org/10.1523/ENEURO.0114-25.2025